Tag: CSL – Seqirus
Australia extends life-saving antivenom partnership with PNG
Australia is bolstering its support for Papua New Guinea's health system by renewing its partnership, which includes supplying antivenom doses and training healthcare workers, for an additional three years until 2027.
CSL’s $800 million vaccine manufacturing facility in Melbourne nears completion
CSL Seqirus has reached a major milestone in the construction of its new cutting-edge manufacturing facility for vaccine and antivenom manufacturing.
TGA approves domestic manufacture of AstraZeneca vaccine
CSL has been given the nod by the Therapeutic Goods Administration (TGA) to commence the manufacture of the AstraZeneca COVID-19 Vaccine (ChAdOx1-S) in Australia.
TGA’s...
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
